Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857100 · ClinicalTrials.gov registry record · NA
Improving Wisely - Polypharmacy
A NA study of Adverse Drug Event, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 11,000
- Enrollment target
- 1
- Study location
NCT03857100: Completed NA study of Adverse Drug Event, sponsored by Johns Hopkins University.
NCT03857100 is a NA study of Adverse Drug Event that has completed, run by Johns Hopkins University. The registered enrollment target is 11,000 participants, above the 4,379-participant average among 5 other Adverse Drug Event trials with a reported enrollment target (151% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03857100, a NA study of Adverse Drug Event, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized controlled trial that uses an audit and feedback intervention to alert primary care physicians who are outliers in one or more metrics related to high risk prescribing of participants' outlier status. Primary care physicians will be randomized to the intervention or control arm, except in California, where all outliers will be notified. The investigators will evaluate the impact of the intervention on prescribing patterns.
Conditions Studied
Interventions
- OTHER Audit and feedback - letter and report
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,000 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2021-01-30 |
| Phase | NA |
What the finished NCT03857100 record still lists
NCT03857100 is an interventional study that assigns participants to a tested intervention. Its 11,000 participants enrollment target places it among the larger protocols in the corpus, above the 4,379-participant average among 5 other Adverse Drug Event trials with a reported enrollment target (151% higher).
The record links to 1 condition, with Adverse Drug Event appearing as the primary indexed condition, and to 1 intervention - of which Audit and feedback - letter and report is the first listed.
NCT03857100 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03857100 about?
NCT03857100 is a clinical study titled "Improving Wisely - Polypharmacy". This is a randomized controlled trial that uses an audit and feedback intervention to alert primary care physicians who are outliers in one or more metrics related to high risk prescribing of participants' outlier status. Primary care physicians will be randomized to the intervention or control arm,...
What is the current status of trial NCT03857100?
This trial is currently completed. It is a NA study. The enrollment target is 11,000 participants. The study started on 2019-01-04. Estimated completion is 2021-01-30.
What conditions does trial NCT03857100 study?
This clinical trial studies the following conditions: Adverse Drug Event.
What interventions are being tested in trial NCT03857100?
The interventions under investigation include: Audit and feedback - letter and report (OTHER).
Who is sponsoring clinical trial NCT03857100?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03857100 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Event
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered
COMPLETED · NA
-
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
COMPLETED · NA
-
Melatonin for Prevention of Kidney Injury
RECRUITING · Phase 3
-
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
COMPLETED
-
Safety of Pediatric COVID-19 Vaccination
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI